Edition:
United Kingdom

Agilent Technologies Inc (A.N)

A.N on New York Stock Exchange

68.92USD
5:38pm BST
Change (% chg)

$0.22 (+0.32%)
Prev Close
$68.70
Open
$68.91
Day's High
$69.21
Day's Low
$68.47
Volume
226,362
Avg. Vol
547,861
52-wk High
$82.26
52-wk Low
$61.01

Latest Key Developments (Source: Significant Developments)

Twist Bioscience-On Dec 7, Court Granted Agilent's Motion To Amend Its Complaint, Permitting Agilent To File Its Second Amended Complaint
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Twist Bioscience Corp ::TWIST BIOSCIENCE - ON DEC 7, COURT GRANTED AGILENT'S MOTION TO AMEND ITS COMPLAINT, PERMITTING AGILENT TO FILE ITS SECOND AMENDED COMPLAINT.TWIST BIOSCIENCE - AGILENT'S NEW COMPLAINT ADDS AMENDED ALLEGATIONS AGAINST CO & ITS CEO EMILY LEPROUST.TWIST BIOSCIENCE - AGILENT'S NEW COMPLAINT ADDS NEW CLAIMS FOR BREACH OF CONTRACT, TRADE SECRET MISAPPROPRIATION AGAINST SIYUAN CHEN, SOLANGE GLAIZE.TWIST BIOSCIENCE - THE COURT DENIED AGILENT’S MOTION FOR A PROTECTIVE ORDER, AND DID NOT SET ANY LIMITS ON DISCOVERY.TWIST BIOSCIENCE - ON DEC 7, COURT SET TRIAL WITH AGILENT TO START ON FEB 24, 2020.  Full Article

Agilent Technologies Increases Cash Dividend To 16.4 Cents Per Share
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Agilent Technologies Inc ::AGILENT TECHNOLOGIES INCREASES CASH DIVIDEND TO 16.4 CENTS PER SHARE.  Full Article

Agilent Companion Diagnostic Gains Expanded FDA Approval In Cervical Cancer
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Agilent Technologies Inc ::AGILENT COMPANION DIAGNOSTIC GAINS EXPANDED FDA APPROVAL IN CERVICAL CANCER.AGILENT TECHNOLOGIES INC - FDA HAS APPROVED ITS DAKO PD-L1 IHC 22C3 PHARMDX ASSAY FOR EXPANDED USE.  Full Article

Alnylam Pharma Co, Agilent Technologies Entered Manufacturing Services Agreement Providing For Supply Of Patisiran Drug Substance By Agilent
Tuesday, 3 Apr 2018 

April 4 (Reuters) - Alnylam Pharmaceuticals ::CO, AGILENT TECHNOLOGIES ENTERED MANUFACTURING SERVICES AGREEMENT PROVIDING FOR SUPPLY OF PATISIRAN DRUG SUBSTANCE BY AGILENT.AGREEMENT HAS INITIAL TERM OF 5 YEARS, WHICH IS SUBJECT TO AUTOMATIC RENEWAL TERMS OF 2 YEARS.PURSUANT TO AGREEMENT, CO REQUIRED TO PROVIDE ROLLING FORECASTS FOR PRODUCT ON QUARTERLY BASIS.‍PURSUANT TO DEAL, AGILENT HAS AGREED TO MANUFACTURE, SUPPLY TO CO, ACTIVE PHARMACEUTICAL INGREDIENTS REQUIRED FOR PATISIRAN FOR COMMERCIAL SALE​.WILL BE REQUIRED TO PROVIDE INITIAL PAYMENT TO COVER RAW MATERIAL PURCHASES AND RESERVE APPROPRIATE RESOURCES UNDER AGREEMENT.  Full Article

Agilent Technologies To Acquire Advanced Analytical Technologies, Inc.
Thursday, 8 Mar 2018 

March 8 (Reuters) - Agilent Technologies Inc ::AGILENT TECHNOLOGIES TO ACQUIRE ADVANCED ANALYTICAL TECHNOLOGIES, INC..‍ANNOUNCED IT HAS SIGNED DEFINITIVE AGREEMENT TO ACQUIRE ADVANCED ANALYTICAL TECHNOLOGIES INC FOR $250 MILLION IN CASH​.  Full Article

Agilent And Imperial College London Announce Collaboration Agreement
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Agilent Technologies Inc ::AGILENT AND IMPERIAL COLLEGE LONDON ANNOUNCE COLLABORATION AGREEMENT.AGILENT TECHNOLOGIES - UNDER AGREEMENT, CO TO SUPPORT IMPERIAL WITH A BROAD RANGE OF INSTRUMENTS TO EQUIP A NEW AGILENT SPONSORED MEASUREMENT SUITE.  Full Article

Agilent Expands Cell Analysis Portfolio With Acquisition Of Luxcel Biosciences
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Agilent Technologies Inc ::AGILENT EXPANDS CELL ANALYSIS PORTFOLIO WITH ACQUISITION OF LUXCEL BIOSCIENCES.HAS ACQUIRED CORK, IRELAND-BASED LUXCEL BIOSCIENCES.‍FINANCIAL TERMS OF DEAL ARE NOT BEING DISCLOSED​.  Full Article

Agilent Technologies Q4 non-gaap earnings per share $0.67
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Agilent Technologies Inc ::Agilent Technologies reports fourth-quarter fiscal year 2017 financial results.Sees FY 2018 non-gaap earnings per share $2.50 to $2.56.Sees Q1 2018 non-gaap earnings per share $0.55 to $0.57.Q4 gaap earnings per share $0.54.Sees FY 2018 revenue $4.72 billion to $4.74 billion.Sees Q1 2018 revenue $1.145 billion to $1.165 billion.Q4 revenue $1.19 billion versus I/B/E/S view $1.17 billion.Q4 earnings per share view $0.62 -- Thomson Reuters I/B/E/S.Q4 non-gaap earnings per share $0.67.Q4 earnings per share view $0.62, revenue view $1.17 billion -- Thomson Reuters I/B/E/S.FY 2018 earnings per share view $2.59, revenue view $4.73 billion -- Thomson Reuters I/B/E/S.FY 2018 earnings per share view $2.59, revenue view $4.73 billion -- Thomson Reuters I/B/E/S.  Full Article

Agilent technologies increases cash dividend to 14.9 cents per share
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Agilent Technologies Inc :Agilent technologies increases cash dividend to 14.9 cents per share.  Full Article

Agilent Technologies receives expanded FDA approval for Dako PD-L1 IHC 22C3 pharmDx
Friday, 22 Sep 2017 

Sept 22 (Reuters) - Agilent Technologies Inc :Agilent Technologies receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 pharmDx companion diagnostic in gastric or gastroesophageal junction (GEJ) cancer.  Full Article

WHO updates its essential medicines list, adds cancer and stroke drugs

GENEVA, July 9 The World Health Organization published an updated list of "essential medicines" on Tuesday, adding drugs for cancer, stroke, rheumatoid arthritis and inflammatory bowel disease among the treatments that should be seen as the standard.